Preferred Label : agonists;
Origin ID : Q000819;
UMLS CUI : C0243192;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- False automatic mappings
- Semantic type(s)
https://www.ema.europa.eu/en/medicines/human/EPAR/paxneury
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
guanfacine
guanfacine
attention deficit disorder with hyperactivity
child
adolescent
Attention deficit disorder of childhood without mention of hyperactivity
drugs, generic
continuity of patient care
administration, oral
tablets
Product containing only guanfacine in oral dose form (medicinal product form)
guanfacine hydrochloride
guanfacine hydrochloride
Delayed-Action preparations
Product containing precisely guanfacine (as guanfacine hydrochloride) 1 milligram/1
each prolonged-release oral tablet (clinical drug)
Product containing precisely guanfacine (as guanfacine hydrochloride) 2 milligram/1
each prolonged-release oral tablet (clinical drug)
Product containing precisely guanfacine (as guanfacine hydrochloride) 3 milligram/1
each prolonged-release oral tablet (clinical drug)
Product containing precisely guanfacine (as guanfacine hydrochloride) 4 milligram/1
each prolonged-release oral tablet (clinical drug)
drug monitoring
product surveillance, postmarketing
drug interactions
drug evaluation, preclinical
receptor, adrenergic, alpha-2A
Alpha-2 adrenergic receptor agonist (disposition)
---
https://www.cochrane.org/fr/CD006318/ADDICTN_traitements-dentretien-pour-les-femmes-enceintes-dependantes-aux-opiaces
2020
false
true
false
United Kingdom
France
pregnancy
narcotics
treatment outcome
drug users
review of literature
french abstract
opioid-related disorders
Pregnant People
---
https://www.cochrane.org/fr/CD010693/des-medicaments-contre-le-diabete-pour-prevenir-les-accidents-vasculaires-cerebraux-et-autres
2019
false
false
false
France
United Kingdom
meta-analysis
french abstract
stroke
secondary prevention
ischemic attack, transient
peroxisome proliferator-activated receptors
treatment outcome
---
https://rmlg.uliege.be/article/2974
2018
false
false
false
false
Belgium
French
journal article
diabetes mellitus, type 2
cardiovascular diseases
hypoglycemic agents
empagliflozin
treatment outcome
empagliflozin
Sodium-Glucose transporter 2
comparative effectiveness research
Liraglutide
liraglutide
Glucagon-Like Peptide-1 Receptor
incretins
case reports
prognosis
cardiovascular diseases
drug therapy, combination
diabetes mellitus, type 2
renal insufficiency, chronic
belgium
insurance, health, reimbursement
Clinical Decision-Making
risk factors
Sodium-Glucose Transporter 2 Inhibitors
benzhydryl compounds
glucosides
---
https://www.ema.europa.eu/medicines/human/EPAR/Ozempic
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
semaglutide
semaglutide
drug approval
europe
treatment outcome
adult
diabetes mellitus, type 2
injections, subcutaneous
Pre-filled Pen Syringe
Glucagon-Like Peptide-1 Receptor
Glycated Hemoglobin
cardiovascular diseases
diabetes complications
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
semaglutide
glucagon-like peptides
glucagon-like peptides
---
https://www.revmed.ch/RMS/2017/RMS-N-571/Options-therapeutiques-chez-un-patient-diabetique-de-type-2-mal-controle-par-une-insuline-basale
2017
false
false
false
Switzerland
French
journal article
diabetes mellitus, type 2
administration, oral
insulin
injections, subcutaneous
hypoglycemic agents
dipeptidyl-peptidase iv inhibitors
SGLT2 Inhibitor
Sodium-Glucose transporter 2
drug therapy, combination
Glucagon-Like Peptide-1 Receptor
drug combinations
Sodium-Glucose Transporter 2 Inhibitors
---
http://www.has-sante.fr/portail/jcms/c_1774157/fr/salvacyl
2014
true
France
French
evaluation of the transparency committee
treatment outcome
Delayed-Action preparations
triptorelin pamoate
insurance, health, reimbursement
gonadotropin-releasing hormone
Paraphilic Disorders
injections, intramuscular
adult
testosterone
triptorelin
---
http://www.revmed.ch/RMS/2014/RMS-N-439/Interet-d-une-combinaison-agoniste-des-recepteurs-du-GLP-1-et-insuline-basale-dans-le-traitement-du-diabete-de-type-2
2014
false
false
false
Switzerland
French
journal article
drug therapy, combination
hypoglycemic agents
diabetes mellitus, type 2
insulin
treatment outcome
Substance with glucagon-like peptide 1 receptor agonist mechanism of action (substance)
incretins
drug combinations
blood glucose
gastric emptying
injections, subcutaneous
Delayed-Action preparations
hyperglycemia, postprandial
semaglutide
rGLP-1 protein
body weight
Liraglutide
Glucagon-Like Peptide-1 Receptor
lixisenatide
hyperglycemia
dulaglutide
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
peptides
venoms
glucagon-like peptide 1
glucagon-like peptide 1
Exenatide
---
http://www.amub-ulb.be/revue-medicale-bruxelles/article/les-nouveaux-anti-diabetiques-oraux-1032
2014
false
false
false
false
Belgium
French
journal article
comparative study
diabetes mellitus, type 2
incretins
hypoglycemic agents
administration, oral
incretins
gastric inhibitory polypeptide
glucagon-like peptide 1
dipeptidyl-peptidase iv inhibitors
dipeptidyl peptidase 4 (DPP-4) inhibitors
other blood glucose lowering drugs, excl. insulins
incretins
hypoglycemic agents
hypoglycemic agents
SLC5A2 protein, human
risk factors
drug therapy, combination
treatment outcome
Glucagon-Like Peptide-1 Receptor
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose transporter 2
---
http://www.cochrane.org/fr/CD002808
2013
United Kingdom
France
French
french abstract
meta-analysis
gonadotropin-releasing hormone
time
fertilization in vitro
treatment outcome
pituitary gland
---
https://smf.swisshealthweb.ch/fr/article/doi/fms.2011.07600/
2011
false
true
false
Switzerland
thrombocytopenia
journal article
receptors, thrombopoietin
---
http://www.cochrane.org/fr/CD008235
2011
false
true
false
France
United Kingdom
receptors, thrombopoietin
receptors, thrombopoietin
treatment outcome
review of literature
french abstract
purpura, thrombocytopenic, idiopathic
---
https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/13541a-fra.php
2011
Canada
French
English
pharmacovigilance note
Cardiotoxicity
risk
gonadotropin-releasing hormone
gonadotropin-releasing hormone
prostatic neoplasms
stroke
myocardial infarction
---
http://www.cochrane.org/fr/CD008046
2011
false
true
false
France
United Kingdom
chorionic gonadotropin
gonadotropin-releasing hormone
oogenesis
treatment outcome
review of literature
french abstract
gonadotropin-releasing hormone
---
https://www.revmed.ch/RMS/2009/RMS-206/Role-et-place-des-analogues-du-GLP-1-dans-le-traitement-du-diabete-de-type-2
2009
false
Switzerland
French
Liraglutide
Glucagon-Like Peptide-1 Receptor
exenatide
liraglutide
diabetes mellitus, type 2
glucagon-like peptide 1
Product containing glucagon-like peptide 1 receptor agonist (product)
Substance with glucagon-like peptide 1 receptor agonist mechanism of action (substance)
hypoglycemic agents
peptides
venoms
journal article
Exenatide
incretins
---
http://www.has-sante.fr/portail/jcms/c_812373/salvacyl-lp-triptoreline-agoniste-de-la-lhrh
2009
false
France
French
guidelines for drug use
evaluation of the transparency committee
treatment outcome
Delayed-Action preparations
triptorelin pamoate
insurance, health, reimbursement
gonadotropin-releasing hormone
Paraphilic Disorders
injections, intramuscular
adult
testosterone
triptorelin
---
http://www.john-libbey-eurotext.fr/fr/revues/medecine/met/e-docs/00/04/41/01/resume.md?type=text.html
2008
France
French
receptors, thrombopoietin
receptors, thrombopoietin
purpura, thrombocytopenic, idiopathic
journal article
---
